Почетна › Беркитов лимфом › Kanzas
Kliničke studije za Беркитов лимфом u državi Kanzas
6 studija za Беркитов лимфом traži učesnike na lokacijama u državi Kanzas.
Gradovi u državi Kanzas
Zvanični tekst studije (na engleskom)
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03739814Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
- Cancer Center of Kansas - Wichita, Wichita
Тражи се учесникФаза 3
Узраст од 18 до 39 · Оба пола · Ажурирано 3. 11. 2026. · NCT03150693Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07069699Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Wesley Medical Center, Wichita
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Mercy Hospital, Kansas City
Тражи се учесникФаза 2
Узраст од 7 до 25 · Оба пола · Ажурирано 19. 8. 2026. · NCT05082519Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
- University of Kansas Cancer Center, Westwood
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 5. 2026. · NCT06879340Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.